{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T20:36:46Z","timestamp":1774903006290,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,3,30]],"date-time":"2014-03-30T00:00:00Z","timestamp":1396137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s13277-014-1820-5","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T13:13:10Z","timestamp":1396098790000},"page":"6467-6474","source":"Crossref","is-referenced-by-count":10,"title":["Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway"],"prefix":"10.1007","volume":"35","author":[{"given":"Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,30]]},"reference":[{"issue":"1","key":"1820_CR1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0308-2261(21)00164-8","volume":"9","author":"JD Rowley","year":"1980","unstructured":"Rowley JD. Ph1-positive leukaemia, including chronic myelogenous leukaemia. Clin Haematol. 1980;9(1):55\u201386.","journal-title":"Clin Haematol"},{"issue":"1","key":"1820_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93\u20139.","journal-title":"Cell"},{"issue":"5531","key":"1820_CR3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876\u201380.","journal-title":"Science"},{"issue":"5","key":"1820_CR4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.leukres.2009.07.012","volume":"34","author":"M Mancini","year":"2010","unstructured":"Mancini M, Corradi V, Petta S, Martinelli G, Barbieri E, Santucci MA. mTOR inhibitor RAD001 (everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res. 2010;34(5):641\u20138.","journal-title":"Leuk Res"},{"issue":"3","key":"1820_CR5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","volume":"18","author":"JV Melo","year":"2004","unstructured":"Melo JV, Deininger MW. Biology of chronic myelogenous leukemia\u2014signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18(3):545\u201368.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"1820_CR6","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","volume":"101","author":"MG Mohi","year":"2004","unstructured":"Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1820_CR7","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2004-10-4003","volume":"106","author":"S Parmar","year":"2005","unstructured":"Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood. 2005;106(7):2436\u201343.","journal-title":"Blood"},{"issue":"2","key":"1820_CR8","first-page":"461","volume":"27","author":"J Li","year":"2012","unstructured":"Li J, Xue L, Hao H, Han Y, Yang J, Luo J. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Oncol Rep. 2012;27(2):461\u20136.","journal-title":"Oncol Rep"},{"issue":"3","key":"1820_CR9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","volume":"33","author":"C Hirase","year":"2009","unstructured":"Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leuk Res. 2009;33(3):450\u20139.","journal-title":"Leuk Res"},{"issue":"4","key":"1820_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.exphem.2011.01.005","volume":"39","author":"A Batista","year":"2011","unstructured":"Batista A, Barata JT, Raderschall E, Sallan SE, Carlesson N, Nadler LM, et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. 2011;39(4):457\u201372.","journal-title":"Exp Hematol"},{"issue":"4","key":"1820_CR11","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","volume":"66","author":"H Yan","year":"2006","unstructured":"Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006;66(4):2305\u201313.","journal-title":"Cancer Res"},{"issue":"1","key":"1820_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ijc.24749","volume":"126","author":"BC Wulff","year":"2010","unstructured":"Wulff BC, Thomas-Ahner JM, Schick JS, Oberyszyn TM. Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs. Int J Cancer. 2010;126(1):11\u20138.","journal-title":"Int J Cancer"},{"issue":"6","key":"1820_CR13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1381612043453126","volume":"10","author":"JF Evans","year":"2004","unstructured":"Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des. 2004;10(6):627\u201334.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1820_CR14","first-page":"223","volume":"18","author":"J Li","year":"2009","unstructured":"Li J, Hao H, Xue L, Wang C, Wang S, Wang R. Expression and significance of COX-2, bcl-2, caspase-3 in diffuse large B-cell lymphoma. J Leuk Lymphoma. 2009;18(4):223\u20135.","journal-title":"J Leuk Lymphoma"},{"issue":"2","key":"1820_CR15","first-page":"147","volume":"40","author":"J Li","year":"2013","unstructured":"Li J, Xue L, Wang C, Wang R, Yang J, Hao H. Effects of celecoxib on proliferation, apoptosis and VEGF expression in NB4 cells. Cancer Res Prev Treat. 2013;40(2):147\u201350.","journal-title":"Cancer Res Prev Treat"},{"issue":"1","key":"1820_CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2004.11.002","volume":"224","author":"J Subhashini","year":"2005","unstructured":"Subhashini J, Mahipal SV, Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. 2005;224(1):31\u201343.","journal-title":"Cancer Lett"},{"issue":"2","key":"1820_CR17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0145-2126(03)00183-8","volume":"28","author":"T Wun","year":"2004","unstructured":"Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res. 2004;28(2):179\u201390.","journal-title":"Leuk Res"},{"issue":"17","key":"1820_CR18","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.4161\/cc.10.17.16460","volume":"10","author":"C Sobolewski","year":"2011","unstructured":"Sobolewski C, Cerella C, Dicato M, Diederich M. Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells. Cell Cycle. 2011;10(17):2978\u201393.","journal-title":"Cell Cycle"},{"issue":"4","key":"1820_CR19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajh.20542","volume":"81","author":"GS Zhang","year":"2006","unstructured":"Zhang GS, Liu DS, Dai CW, Li RJ. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol. 2006;81(4):242\u201355.","journal-title":"Am J Hematol"},{"issue":"31","key":"1820_CR20","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.1074\/jbc.M201119200","volume":"277","author":"S Arico","year":"2002","unstructured":"Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002;277(31):27613\u201321.","journal-title":"J Biol Chem"},{"issue":"4","key":"1820_CR21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1158\/0008-5472.CAN-03-2396","volume":"64","author":"SK Kulp","year":"2004","unstructured":"Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, et al. 3-Phosphoinositide-dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004;64(4):1444\u201351.","journal-title":"Cancer Res"},{"issue":"23","key":"1820_CR22","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/jnci\/94.23.1745","volume":"94","author":"J Zhu","year":"2002","unstructured":"Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst. 2002;94(23):1745\u201357.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1820_CR23","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1124\/mol.106.023911","volume":"70","author":"PH Tseng","year":"2006","unstructured":"Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006;70(5):1534\u201341.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1820_CR24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.179325","volume":"338","author":"X Fan","year":"2011","unstructured":"Fan X, Takahashi-Yanaga F, Morimoto S, Zhan DY, Igawa K, Tomooka K, et al. Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. J Pharmacol Exp Ther. 2011;338(1):2\u201311.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1820_CR25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1245\/s10434-010-1268-9","volume":"18","author":"YJ Zhang","year":"2011","unstructured":"Zhang YJ, Bao YJ, Dai Q, Yang WY, Cheng P, Zhu LM, et al. mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol. 2011;18(2):580\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1820_CR26","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/en.2012-2074","volume":"154","author":"BT Vo","year":"2013","unstructured":"Vo BT, Morton Jr D, Komaragiri S, Millena AC, Leath C, Khan SA. TGF-\u03b2 effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K\/AKT\/mTOR pathway. Endocrinology. 2013;154(5):1768\u201379.","journal-title":"Endocrinology"},{"key":"1820_CR27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-2094-9-2","volume":"9","author":"AC Oliveira de","year":"2012","unstructured":"de Oliveira AC, Candelario-Jalil E, Langbein J, Wendeburg L, Bhatia HS, Schlachetzki JC, et al. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation. 2012;9:2.","journal-title":"J Neuroinflammation"},{"issue":"8","key":"1820_CR28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/glia.20658","volume":"56","author":"AC Oliveira de","year":"2008","unstructured":"de Oliveira AC, Candelario-Jalil E, Bhatia HS, Lieb K, H\u00fcll M, Fiebich BL. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia. 2008;56(8):844\u201355.","journal-title":"Glia"},{"issue":"1","key":"1820_CR29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20131080","volume":"211","author":"C Li","year":"2014","unstructured":"Li C, Lee PS, Sun Y, Gu X, Zhang E, Guo Y, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med. 2014;211(1):15\u201328.","journal-title":"J Exp Med"},{"issue":"1","key":"1820_CR30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2362.2007.01892.x","volume":"38","author":"C Sillaber","year":"2008","unstructured":"Sillaber C, Mayerhofer M, B\u00f6hm A, Vales A, Gruze A, Aichberger KJ, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest. 2008;38(1):43\u201352.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"1820_CR31","first-page":"1167","volume":"23","author":"ZG Wang","year":"2010","unstructured":"Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep. 2010;23(4):1167\u201372.","journal-title":"Oncol Rep"},{"issue":"5","key":"1820_CR32","first-page":"1231","volume":"34","author":"R Mishra","year":"2009","unstructured":"Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, et al. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. Int J Oncol. 2009;34(5):1231\u201340.","journal-title":"Int J Oncol"},{"issue":"5","key":"1820_CR33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320\u20134.","journal-title":"Am J Hematol"},{"issue":"8","key":"1820_CR34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.leukres.2009.12.011","volume":"34","author":"T Nagai","year":"2010","unstructured":"Nagai T, Ohmine K, Fujiwara S, Uesawa M, Sakurai C, Ozawa K. Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. Leuk Res. 2010;34(8):1057\u201363.","journal-title":"Leuk Res"},{"issue":"11","key":"1820_CR35","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","volume":"13","author":"RT Abraham","year":"2007","unstructured":"Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 2007;13(11):3109\u201314.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1820_CR36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.21265","volume":"104","author":"K Margolin","year":"2005","unstructured":"Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104(5):1045\u20138.","journal-title":"Cancer"},{"issue":"10","key":"1820_CR37","first-page":"4017","volume":"30","author":"A Bundscherer","year":"2010","unstructured":"Bundscherer A, Vogt T, K\u00f6hl G, Landthaler M, Hafner C. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. Anticancer Res. 2010;30(10):4017\u201323.","journal-title":"Anticancer Res"},{"issue":"8","key":"1820_CR38","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1158\/1055-9965.EPI-11-0411","volume":"20","author":"JA Ross","year":"2011","unstructured":"Ross JA, Blair CK, Cerhan JR, Soler JT, Hirsch BA, Roesler MA, et al. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1741\u201350.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"1820_CR39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/omi.2010.0092","volume":"15","author":"M Cervello","year":"2011","unstructured":"Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, Lampiasi N, et al. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS. 2011;15(6):383\u201392.","journal-title":"OMICS"},{"issue":"11","key":"1820_CR40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjc.6604049","volume":"97","author":"AH Sch\u00f6nthal","year":"2007","unstructured":"Sch\u00f6nthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer. 2007;97(11):1465\u20138.","journal-title":"Br J Cancer"},{"issue":"4","key":"1820_CR41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s13277-012-0324-4","volume":"33","author":"YX Wang","year":"2012","unstructured":"Wang YX, Gao JX, Wang XY, Zhang L, Liu CM. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biol. 2012;33(4):957\u201366.","journal-title":"Tumour Biol"},{"issue":"4","key":"1820_CR42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2744(199908)25:4<231::AID-MC1>3.0.CO;2-F","volume":"25","author":"SM Fischer","year":"1999","unstructured":"Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25(4):231\u201340.","journal-title":"Mol Carcinog"},{"issue":"8","key":"1820_CR43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/01902140150216783","volume":"26","author":"R Yao","year":"2000","unstructured":"Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal antiinflammatory drugs\u2019 chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res. 2000;26(8):731\u201342.","journal-title":"Exp Lung Res"},{"issue":"3 Pt 1","key":"1820_CR44","first-page":"820","volume":"164","author":"XH Liu","year":"2000","unstructured":"Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3 Pt 1):820\u20135.","journal-title":"J Urol"},{"issue":"2","key":"1820_CR45","first-page":"547","volume":"19","author":"A Bundscherer","year":"2008","unstructured":"Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep. 2008;19(2):547\u201353.","journal-title":"Oncol Rep"},{"issue":"3","key":"1820_CR46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50380","volume":"38","author":"J Leng","year":"2003","unstructured":"Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38(3):756\u201368.","journal-title":"Hepatology"},{"issue":"4","key":"1820_CR47","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1053\/j.gastro.2008.07.012","volume":"135","author":"S Ladu","year":"2008","unstructured":"Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA\/Akt\/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 2008;135(4):1322\u201332.","journal-title":"Gastroenterology"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1820-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-1820-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1820-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T13:32:57Z","timestamp":1716643977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-1820-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,30]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-1820-5","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,30]]}}}